Liver Transplantation News and Research RSS Feed - Liver Transplantation News and Research

Dr. Hans Clevers receives ISSCR's McEwen Award for Innovation

Dr. Hans Clevers receives ISSCR's McEwen Award for Innovation

The International Society for Stem Cell Research has awarded Dr. Hans Clevers, senior author on two important papers published recently in the scientific journal Cell, the society's McEwen Award for Innovation. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

UCLA transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions. [More]
Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus to exhibit new mRNA therapeutics pipeline at two healthcare conferences

Arcturus Therapeutics Inc., developing the 'next wave' of RNA medicines, today announced that Joseph Payne, President and Chief Executive Officer, is scheduled to present a corporate overview, including the company's new messenger RNA (mRNA) therapeutics pipeline, at two upcoming healthcare conferences. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

Ashish Nimgaonkar wins AGA-Boston Scientific Career Development Technology & Innovation Award

The American Gastroenterological Association Research Foundation is pleased to announce that Ashish Nimgaonkar, MBBS, MTech, MS, from John Hopkins University, has received the inaugural AGA-Boston Scientific Career Development Technology & Innovation Award. This award is graciously supported by a grant from Boston Scientific, a leading innovator of medical solutions. [More]
New treatment regimen for hepatitis C in transplant patients produces promising results

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine. [More]
Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

Obeticholic acid improves liver health in people with nonalcoholic steatohepatitis

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol. [More]
Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai scientists test ELAD bioartificial liver support system for patients with acute liver failure

Cedars-Sinai physicians and scientists are testing a novel, human cell based, bioartificial liver support system for patients with acute liver failure, often a fatal diagnosis. [More]
Study finds that ambivalence is common among liver donor candidates

Study finds that ambivalence is common among liver donor candidates

Living donors are important to increasing the number of viable grafts for liver transplantation. A new study published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, found that ambivalence is common among donor candidates. [More]
Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

Liver injury caused by herbals and dietary supplements increases 20% in U.S. study group

New research shows that liver injury caused by herbals and dietary supplements increased from 7% to 20% in a U.S. study group over a ten-year period. [More]
Research findings call for clinical testing of relevant drugs to prevent NASH

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation. [More]
RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

RI Defeats Hepatitis C project aims to eliminate HCV in Rhode Island

Lynn E. Taylor, M.D., director of The Miriam Hospital's HIV/Viral Hepatitis Coinfection program, states in the July, 2014 Rhode Island Medical Journal special edition, "RI Defeats Hep C" that eliminating hepatitis c virus infection (hep c or HCV) is feasible, can provide economic benefits, enhance capacity to address other health challenges, and improve health care disparities. [More]
Many liver transplant patients want to be involved in the decision of whether to accept the organ

Many liver transplant patients want to be involved in the decision of whether to accept the organ

A novel study reveals that more than half of liver transplant patients want to be informed of donor risk at the time a liver is offered for transplantation. Nearly 80% of those patients want to be involved in the decision of whether or not to accept the organ according to findings published in Liver Transplantation, a journal of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. [More]
Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma

Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. [More]
Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. [More]
U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

A simple blood test can detect if a person is one of the two billion people worldwide infected with hepatitis B. And now the U.S. Preventive Services Task Force recommends that all teens and adults who are high risk for hepatitis B get screened for the infection. [More]
OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products. [More]
U.S. urges daily pill for those at risk of AIDS

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions. [More]
uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

uEtG accurately detects alcohol consumption in liver transplant candidates and recipients

Researchers from Italy confirm that urinary ethyl glucuronide (uEtG) accurately detects alcohol consumption in liver transplant candidates and recipients. [More]